Online inquiry

IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4500MR)

This product GTTS-WQ4500MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CXCL10 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001565.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3627
UniProt ID P02778
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4500MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2776MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ8288MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HM10560A
GTTS-WQ661MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ13632MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ2411MR IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 145
GTTS-WQ5598MR IVTScrip™ mRNA-Anti-IL13, CDP7766(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP7766
GTTS-WQ10771MR IVTScrip™ mRNA-Anti-FGFR4, M-70(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-70
GTTS-WQ11733MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW